672 related articles for article (PubMed ID: 34925359)
61. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
62. Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial.
Speich B; Chammartin F; Abela IA; Amico P; Stoeckle MP; Eichenberger AL; Hasse B; Braun DL; Schuurmans MM; Müller TF; Tamm M; Audigé A; Mueller NJ; Rauch A; Günthard HF; Koller MT; Trkola A; Briel M; Kusejko K; Bucher HC;
Clin Infect Dis; 2022 Aug; 75(1):e585-e593. PubMed ID: 35234868
[TBL] [Abstract][Full Text] [Related]
63. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
Thuluvath PJ; Robarts P; Chauhan M
J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
[TBL] [Abstract][Full Text] [Related]
64. Factors associated with anti-SARS-CoV-2 spike antibody titers after a second BNT162b2 mRNA COVID-19 vaccination in Japanese hemodialysis patients.
Hirai K; Shimotashiro M; Sonoda T; Okumura T; Ookawara S; Morishita Y
Clin Exp Nephrol; 2022 Sep; 26(9):925-932. PubMed ID: 35426594
[TBL] [Abstract][Full Text] [Related]
65. Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination.
Keeshan A; Galipeau Y; Heiskanen A; Collins E; McCluskie PS; Arnold C; Saginur R; Booth R; Little J; McGuinty M; Buchan CA; Crawley A; Langlois MA; Cooper C
BMJ Open; 2023 Oct; 13(10):e077714. PubMed ID: 37907304
[TBL] [Abstract][Full Text] [Related]
66. Early human B cell signatures of the primary antibody response to mRNA vaccination.
Kardava L; Rachmaninoff N; Lau WW; Buckner CM; Trihemasava K; Blazkova J; Lopes de Assis F; Wang W; Zhang X; Wang Y; Chiang CI; Narpala S; McCormack GE; Liu C; Seamon CA; Sneller MC; O'Connell S; Li Y; McDermott AB; Chun TW; Fauci AS; Tsang JS; Moir S
Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2204607119. PubMed ID: 35759653
[TBL] [Abstract][Full Text] [Related]
67. Dialysis modality, humoral response to vaccine, and SARS-CoV-2 infection risk: Comparative prospective evaluation.
Bnaya A; Nacasch N; Einbinder Y; Shavit L; Erez D; Shashar M; Grupper A; Benchetrit S; Wand O; Cohen-Hagai K
Semin Dial; 2023; 36(5):382-389. PubMed ID: 37042666
[TBL] [Abstract][Full Text] [Related]
68. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
Front Immunol; 2021; 12():778679. PubMed ID: 34868051
[TBL] [Abstract][Full Text] [Related]
69. Serologic Status According Severe Acute Respiratory Syndrome Coronavirus 2 in Patients After Orthotopic Heart Transplantation.
Kuczaj A; Przybyłowski P
Transplant Proc; 2022 May; 54(4):901-904. PubMed ID: 35414422
[TBL] [Abstract][Full Text] [Related]
70. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
71. Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals.
Portillo V; Fedeli C; Ustero Alonso P; Petignat I; Mereles Costa EC; Sulstarova A; Jaksic C; Yerly S; Calmy A
Front Immunol; 2021; 12():820126. PubMed ID: 35222357
[TBL] [Abstract][Full Text] [Related]
72. Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents.
Kamei K; Ogura M; Sato M; Nishi K; Shoji K; Funaki T; Ogimi C; Ito S
Pediatr Nephrol; 2023 Apr; 38(4):1099-1106. PubMed ID: 35913562
[TBL] [Abstract][Full Text] [Related]
73. Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus.
Kikuchi J; Kondo Y; Kojima S; Kasai S; Sakai Y; Takeshita M; Hiramoto K; Saito S; Fukui H; Hanaoka H; Suzuki K; Kaneko Y
Immunol Med; 2024 Jun; 47(2):76-84. PubMed ID: 38189429
[TBL] [Abstract][Full Text] [Related]
74. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
[TBL] [Abstract][Full Text] [Related]
75. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients.
Longlune N; Nogier MB; Miedougé M; Gabilan C; Cartou C; Seigneuric B; Del Bello A; Marion O; Faguer S; Izopet J; Kamar N
Nephrol Dial Transplant; 2021 Aug; 36(9):1704-1709. PubMed ID: 34057463
[TBL] [Abstract][Full Text] [Related]
76. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
77. Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients.
Bertrand D; Hamzaoui M; Lemée V; Lamulle J; Hanoy M; Laurent C; Lebourg L; Etienne I; Lemoine M; Le Roy F; Nezam D; Plantier JC; Boyer O; Guerrot D; Candon S
J Am Soc Nephrol; 2021 Sep; 32(9):2147-2152. PubMed ID: 34112706
[TBL] [Abstract][Full Text] [Related]
78. Immunogenicity of SARS-CoV-2 Vaccine in Dialysis.
Lacson E; Argyropoulos CP; Manley HJ; Aweh G; Chin AI; Salman LH; Hsu CM; Johnson DS; Weiner DE
J Am Soc Nephrol; 2021 Nov; 32(11):2735-2742. PubMed ID: 34348908
[TBL] [Abstract][Full Text] [Related]
79. Local and Systemic Immunity Are Impaired in End-Stage-Renal-Disease Patients Treated With Hemodialysis, Peritoneal Dialysis and Kidney Transplant Recipients Immunized With BNT162b2 Pfizer-BioNTech SARS-CoV-2 Vaccine.
Piotrowska M; Zieliński M; Tylicki L; Biedunkiewicz B; Kubanek A; Ślizień Z; Polewska K; Tylicki P; Muchlado M; Sakowska J; Renke M; Sudoł A; Dąbrowska M; Lichodziejewska-Niemierko M; Smiatacz T; Dębska-Ślizień A; Trzonkowski P
Front Immunol; 2022; 13():832924. PubMed ID: 35935974
[TBL] [Abstract][Full Text] [Related]
80. Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients.
Giuliano A; Kuter B; Pilon-Thomas S; Whiting J; Mo Q; Leav B; Sirak B; Cubitt C; Dukes C; Isaacs-Soriano K; Kennedy K; Ball S; Dong N; Jain A; Hwu P; Lancet J
Cancer Commun (Lond); 2023 Jul; 43(7):749-764. PubMed ID: 37377402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
